1. Patient Care
  2. Department of Radiology
  3. Department of Radiology Faculty
  4. Annapurneswara Rao Chimpiri MBBS FRCR

Annapurneswara Rao Chimpiri MBBS FRCR


  • Assistant Professor of Clinical Radiology/Attending Physician

Board Certification

  • American Board of Radiology

Education

Medical School
  • Rangaraya Medical College,Kakinada, India
     

Training

Residency Training
  • West Yorkshire Radiology training program, Leeds, UK
Fellowship Training
  • Abdominal Imaging at Cleveland Clinic, Ohio

Contact Information

HSC Level 4, Room 120
Stony Brook, NY 11794-8460
spaceTelephone Ph.:
Fax Fax: 
  • Honors
  • Publications
  • Research Interests
    • The Use of MRI in the Pre-surgical Evaluation of Patients With Androgen Insensitivity Syndrome: Sana Khan, Lisa Mannel. Christian L Koopman,  Rao Chimpiri, Karl R. Hansen, LaTasha B. Craig, Journal of Pediatric and Adolescent Gynecology (in press)
    • Surgical reconstitution of a unilaterally avulsed symptomatic puborectalis muscle using autologous fascia lata: Shobeiri SA, Chimpiri AR, Allen A, Nihira MA, Quiroz LH; Obstet Gynecol. 2009 Aug;114 (2 Pt 2):480-2
    • Pancreatico pleural fistula: Ali T, Srinivasan N, Le V, Chimpiri AR, Tierney WM; Pancreas.2009 Jan; 38(1):e26-31
    • Superior mesenteric artery thrombosis managed percutaneously by timely combining aspiration thrombectomy with angioplasty and stents: Gupta R, Chimpiri AR, Saucedo JF; J Thromb Thrombolysis. 2010 Jan;29(1):105-7
    • Renal Vascular Lesions: Diagnosis and Endovascular Management: Chimpiri,AR &Natarajan,B; Seminars in Interventional Radiology, V 26, No3, Sept 2009
    • Visceral Arteriography in Trauma: Chimpiri,AR &Natarajan,B; Seminars in Interventional Radiology, Vol 26, No 3, Sept 2009
    • Utility of Hepatocyte specific contrast agent, EOVIST, with case examples: Keller Roman, Chimpiri A.Rao; American College of Radiology website, Case-In Point, May 24, 2010
    • Magnetic resonance Imaging of Solitary Fibrous tumor in pelvis: Boe, Justin; Chimpiri A. Rao; Journal of Radiology Case reports: July 2010
    • MRCP as a Diagnostic Study For Pleuropancreatic Fistula: Ali T, Srinivasan N, Le V, Chimpiri AR and Tierney WM; The American Journal of Gastroenterology (2008) 103, S60–S95
      • Role of CT in pancreatic cancer patients having undergone curative surgery; Principle Investigator; IRB14095; University of Oklahoma
      • Cervical cancer lymph node imaging study; Principle Investigator; IRB14100; University of Oklahoma
      • Urothelial tract cancer imaging using CT urography with low dose diuretic and multiphasic post intravenous contrast administration; Principle Investigator; IRB14440; University of Oklahoma
      • Pancreatico-pleural fistula; Principle Investigator; IRB14549; University of Oklahoma
      • High resolution 3D magnetic resonance imaging of Pancreatic duct disruption; Principle Investigator IRB 13622; University of Oklahoma
      • MRI findings of a solitary fibrous tumor in pelvis; Principle Investigator; IRB 13910; University of Oklahoma
      • MRI signal changes in evolution of free and contained blood in Abdomen and pelvis; Principle Investigator; IRB14012; University of Oklahoma
      • Multiphasic enhancement characteristics of telangiectatic focal nodular hyperplasia; Principle Investigator; IRB14057; University of Oklahoma
      • FDG PET/CT, Contrast enhanced CT and MRI findings in Telangiectatic focal nodular hyperplasia; Co- Principle Investigator; IRB14548; University of Oklahoma
      • Bilateral Renal vascular malformations; Principle Investigator; IRB13911; University of Oklahoma
      • Phase III trial of Irinotecan/5FU/Leucovorin or Oxaliplatin/5FU/Leucovorin with Bevacizumab or Cetuximab or with the combination of Bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of colon or rectum; Sub Investigator; IRB 12925; University of Oklahoma
      • Randomized, open label, controlled phase II trial of combination chemotherapy with or without Panitumumab as first line treatment of subjects with metastatic or recurrent head and neck cancer and cross over second line panitumumab monotherapy; Sub Investigator; IRB13353; University of Oklahoma
      • Positron emission tomography pre and post treatment assessment for locally advanced non small cell lung carcinoma; Sub Investigator; IRB 13516; University of Oklahoma
      • Randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound NAB-paclitaxel or ixabepilone combined with Bevacizumab as first line therapy for locally recurrent or metastatic breast cancer; Sub Investigator; IRB 14337; University of Oklahoma
      • Phase II randomized open label study of neratinib versus lapatinib plus ccpecitabine for the treatment of erbb-2 positive locally advanced or metastatic breast cancer; Sub Investigator; IRB14470; University of Oklahoma
      • Phase III randomized trial of Chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer; Sub Investigator; IRB14413; University of Oklahoma
      • Randomized phase III trial study of weekly abi-007 plus gemcitabine versus gemcitabine alone in patients with metastatic adenoacarcinoma of pancreas; Sub Investigator; IRB 14746; University of Oklahoma
      • Randomized phase III double blind, placebo controlled trial of sunitinib as maintenance therapy in non progressing patients following an initial four cycles of platinum based combination chemotherapy in advanced stage IIIb/IV; Sub Investigator; IRB 14950; University of Oklahoma
      • Open label, multicenter phase II study to compare the efficacy and safety of rad001 as first line followed by second line sunitinib versus sunitinib as first line followed by second line rad001 in the treatment of patients with metastatic renal cell carcinoma; Sub Investigator; IRB15049; University of Oklahoma
      • Randomized placebo controlled phase I/II study of ARQ 197 in combination with irinotecan and cetuximab in subjects with metastatic colorectal cancer with wild type KRAS who have received front line systemic therapy; Sub Investigator; IRB15261; University of Oklahoma
      • Phase III randomized double blind study to assess the efficacy and safety of perifoscine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer; Sub Investigator; IRB15262; University of Oklahoma
      Phase III study of chemotherapy and chemo radiotherapy with or without herpacute pancreatic vaccine in subjects with surgically resected pancreatic cancer; Sub Investigator; IRB15321; University of Oklahoma